Alexion Pharmaceuticals’ Co-Development Partnership with Complement Pharma

Foley Hoag LLP recently advised global biopharmaceutical company Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a partnership with Complement Pharma to co-develop a pre-clinical C6 complement inhibitor for…

This content is for members only.
Login to Read More Join Now
Avatar

Author: Ambrogio Visconti

This content is for members only.
Login to Read More Join Now